As far as acne goes, if we analyze what is new in recent years, we have the integration of groups with a
special focus in acne, teams concerned about providing the best options and recommendations to the
whole dermatological community about this worldwide condition, about this disease affecting the
totality of young people between 13 and 22 years old. A condition which, over the years, we have seen
spreading to older population. And which represents a true problem in the daily life of these people.
These teams are interested in all aspects, starting with the research stage, since one of the problems we
are observing is, for example, the resistance to antibiotics which is what we use the most to treat acne.
If this continues to grow, then new people exposing to these resistant bacteria would have less
possibilities of obtaining an effective answer to treatment. That, on the one hand, and on the other, the
new acquisitions we have for the treatment of this condition would be the combination of medications
which are manufactured by well-reputed commercial laboratories who follow all standards pertaining
to the pharmacological industry so that they are more effective against this condition. Currently, we
live in a time when people want quick solutions. They don’t want this problem to progress. We, the
physicians, also want to provide treatment and, as much as possible, we want treatment to be timely.
Early treatments that prevent scarring, which, unfortunately, affects patients and which we, the
dermatologists consider not only as skin scars, but scars of the soul. When questionnaires about the
quality of life are applied to patients, we can see that they are much more severely affected if we
compare it with other diseases such as hypertension, diabetes, psoriaris. It makes young people alter
their daily lives, their working activities, their interrelation activities. That is why it is so important to
treat acne. We could then summarize that, as far is what new is, it would be the creation of expert
groups who are interested in providing to dermatologists with treatment algorithms, favoring, for
example, research activities, which update us on where we are standing in the world, what the status on
resistance is, how we are standing as far as adherence, and generate also communication and generate
strategies to decrease this situation. From the point of view of other developments, well, that is always
growing. We have, from the therapeutic point of view, besides all the pharmacological developments,
other breakthroughs in the field of lasers, in the field of lights. Because there will be patients, for
example, pregnant women, who can not have access to systemic medications, because of their
pregnancy and so they will have to use these other tools.
